** Shares of ophthalmic medical device company RxSight RXST.O fall 33% to $8.55 in extended trading
** RXST cut its 2025 sales forecast to the range of $120 million to $130 million, vs prior expectation of $160 million to $175 million
** Analysts, on average, expect 2025 sales to reach $167.6 million, according to data compiled by LSEG
** Company also expects preliminary Q2 sales to be about $33.6 million, below analysts' estimates of $39.8 million
** J.P. Morgan analysts say the company's update reflects a "continued worsening of trends first seen last quarter rather than a hopeful improvement, a concerning trend set to continue into 2H25 with no clear resolution in sight"
** Stock down 62.8%, YTD
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。